Navigation Links
Dendreon Reports Second Quarter 2009 Financial Results

SEATTLE, Aug. 11 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today reported results for the quarter ended June 30, 2009. Revenue for the second quarter of 2009 was $25,000 compared to $26,000 for the quarter ended June 30, 2008. Revenue for the six months ended June 30, 2009 was $55,000 compared to $57,000 for the six months ended June 30, 2008.

Dendreon's total operating expenses for the second quarter of 2009 were $20.9 million compared to $18.6 million in 2008. Dendreon's total operating expenses for the six months ended June 30, 2009 were $37.9 million compared to $37.8 million for the same period in 2008. The net loss for the quarter ended June 30, 2009 was $126.7 million, or $1.20 per share, compared to a net loss of $16.5 million, or $0.18 per share, for the quarter ended June 30, 2008. The net loss for the quarter ended June 30, 2009 includes a non-cash charge of $105.8 million or $1.00 per share, compared to a non-cash gain of $2.4 million or $0.03 per share, for the quarter ended June 30, 2008 associated with the revaluation of warrants. The net loss for the six months ended June 30, 2009 was $142.1 million, or $1.41 per share, compared to $36.0 million, or $0.41 per share for the six months ended June 30, 2008. The net loss for the six months ended June 30, 2009 includes a non-cash charge of $103.4 million or $1.03 per share associated with the revaluation of warrants, compared to a non-cash gain of $2.4 million or $0.03 per share, for the six months ended June 30, 2008.

Cash, cash equivalents and short-term and long-term investments at June 30, 2009 totaled $287.5 million which includes approximately $221 million in net proceeds from the May 2009 stock offering. This compares with $108.5 million at December 31, 2008.

Recent Events

  • Reported final analysis of the IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment) Phase 3 trial for PROVENGE(R) (sipuleucel-T) which demonstrated a statistically significant increase in overall survival in patients with advanced prostate cancer. Data were presented at the American Urological Association (AUA) Annual Meeting in April. Based on these data, the Company intends to amend its Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA), for PROVENGE in the fourth quarter of this year.
  • Results from an integrated analysis of two Phase 3 studies of PROVENGE, D9901 and D9902A, were published in August 15, 2009 edition of Cancer. The data demonstrates a survival advantage for patients randomized to PROVENGE versus those randomized to placebo.
  • Completed a stock offering with net proceeds totaling approximately $221 million. Approximately 12 million shares were issued to the public at a price of $19.20 per share.
  • Initiated construction of the remaining 75 percent capacity of its lead manufacturing facility in Morris Plains, N.J. The Company expects to substantially complete construction by April 2010. The Company intends to launch PROVENGE into the marketplace from the portion of the facility that is currently completed and has been performing clinical manufacturing.
  • Executed lease agreements for additional manufacturing facilities in Atlanta, Ga. and Orange County, Calif. The Company expects additional capacity from these facilities to be available to ship commercial product in the second half of 2011.
  • "The company achieved a major milestone with the positive results from our Phase 3 IMPACT trial for PROVENGE. We are actively building out the infrastructure necessary to supply PROVENGE to the many patients with advanced prostate cancer who have few appealing treatment options," said Mitchell H. Gold, M.D., president and chief executive officer of Dendreon. "Our top priority remains working through the regulatory process with the FDA, and we remain on track for filing the amendment to our BLA in the fourth quarter of this year."

Conference Call Information

Dendreon will host a conference call today at 8:30 a.m. PT, 11:30 a.m. ET. To access the live call, dial 1-877-548-7903 (domestic) or +1 719-325-4873 (international). The call will also be audio webcast and will be available from the Company's website at under the "Investor/Webcasts and Presentations" section. A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-888-203-1112 or +1-719-457-0820 for international callers; the conference ID number is 3674422. The replay will be available from 2:30 pm ET on Tuesday, August 11 until 11:59 pm ET on Thursday, August 13. In addition, the webcast will be archived for on-demand listening for 30 days at

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington, and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit

This news release contains forward-looking statements that are subject to risks and uncertainties. Factors that could affect these forward-looking statements include, but are not limited to, developments affecting Dendreon's business and prospects, including progress on the commercialization efforts for PROVENGE and requisite receipt of FDA licensure for marketing and the risk that additional capital could be needed in the future for the potential commercialization of PROVENGE. Information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at Dendreon cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to Dendreon on the date hereof, and Dendreon undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.

                               DENDREON CORPORATION
                     (in thousands, except per share amounts)

                                 Three months ended      Six months ended
                                      June 30,               June 30,
                                 ------------------      ----------------
                                 2009          2008       2009      2008
                                 ----          ----       ----      ----

    Revenue                       $25           $26        $55       $57

    Operating expenses:
        Research and
         development           13,321        13,193     25,119    26,671
        General and
         administrative         7,608         5,420     12,825    11,095
                                -----         -----     ------    ------
    Total operating
     expenses                  20,929        18,613     37,944    37,766
                               ------        ------     ------    ------
    Loss from operations      (20,904)      (18,587)   (37,889)  (37,709)
    Interest income               196           951        529     2,088
    Interest expense             (213)       (1,246)    (1,324)   (2,777)
    Gain (loss) from
     valuation  of
     warrant liability       (105,796)        2,368   (103,417)    2,368
                             --------         -----   --------     -----
    Net loss                $(126,717)     $(16,514) $(142,101) $(36,030)
                            =========      ========  =========  ========

    Basic and diluted net
    loss per share             $(1.20)       $(0.18)    $(1.41)   $(0.41)
                               ======        ======     ======    ======

    Shares used in
     of basic and
         diluted net loss     -------        ------    -------    ------
          per share           105,880        91,217    100,851    87,265
                              =======        ======    =======    ======

                                      June 30,     December 31,
                                        2009          2008
                                        ----          ----
    Balance Sheet Data:
    Cash and cash equivalents         $266,122       $59,523
    Short-term investments              21,334        45,638
    Long-term investments                    -         3,386
    Prepaid antigen costs               18,975             -
    Total assets                       352,703       147,204
    Warrant liability                  117,607        14,190
    Convertible senior
     subordinated notes                 52,535        85,250
    Total stockholders' equity         160,746        27,006

SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
3. Dendreon Secures $130 Million Committed Equity Financing Facility
4. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
5. Dendreon Reports Third Quarter 2007 Financial Results
6. Dendreon Promotes Dr. Mark Frohlich to Senior Vice President of Clinical Affairs and Chief Medical Officer
7. Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
8. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
9. -Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM ET-
10. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
11. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
Post Your Comments:
(Date:10/10/2017)... ... October 10, 2017 , ... For the second time in ... STEM Mentoring Award. Representatives of the FirstHand program travelled to Washington, D.C. Tuesday, ... , US2020’s mission is to change the trajectory of STEM education in America ...
(Date:10/10/2017)... Calif. , Oct. 10, 2017 SomaGenics ... from the NIH to develop RealSeq®-SC (Single Cell), expected ... for profiling small RNAs (including microRNAs) from single cells ... Program highlights the need to accelerate development of approaches ... "New techniques for measuring levels ...
(Date:10/9/2017)... 2017  BioTech Holdings announced today identification and ... ProCell stem cell therapy prevents limb loss in ... demonstrated that treatment with ProCell resulted in more ... compared to standard bone marrow stem cell administration.  ... reduction of therapeutic effect.  ...
(Date:10/9/2017)... Arizona (PRWEB) , ... October 09, 2017 , ... ... Kindred, a four-tiered line of medical marijuana products targeting the needs of consumers ... and packaging of Kindred takes place in Phoenix, Arizona. , As operators of ...
Breaking Biology Technology:
(Date:3/30/2017)... , March 30, 2017 The research team ... for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D fingerprint ... new realm of speed and accuracy for use in identification, crime ... affordable cost. ... A ...
(Date:3/28/2017)... -- The report "Video Surveillance Market by ... Devices), Software (Video Analytics, VMS), and Service (VSaaS, Installation ... 2022", published by MarketsandMarkets, the market was valued at ... reach USD 75.64 Billion by 2022, at a CAGR ... considered for the study is 2016 and the forecast ...
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... - Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle ... around 15.1% over the next decade to reach approximately $1,580 million ... estimates and forecasts for all the given segments on global as ...
Breaking Biology News(10 mins):